Vertex PharmaceuticalsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B in Q2 2026, with TRIKAFTA/KAFTRIO its largest revenue segment at 78%.
Vertex PharmaceuticalsVertex sells CFTR modulators (Trikafta/Kaftrio and Alyftrek) that treat most people with cystic fibrosis in core markets. Non-CF products are Casgevy for sickle cell disease and beta thalassemia, and Journavx (suzetrigine) for acute pain.
Vertex Pharmaceuticals (VRTX) is a Biotechnology company. Vertex sells CFTR modulators (Trikafta/Kaftrio and Alyftrek) that treat most people with cystic fibrosis in core markets. Non-CF products are Casgevy for sickle cell disease and beta thalassemia, and Journavx (suzetrigine) for acute pain. It was founded in 1989, is headquartered in Boston, Massachusetts and employs about 6,400 people.
As of 2026-Q2, Vertex Pharmaceuticals's revenue breaks down across TRIKAFTA/KAFTRIO (78%), ALYFTREK (18%), Manufactured Product, Other (4%). See the revenue-by-segment chart for the full mix.
Track Vertex Pharmaceuticals's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.
Sterling groups Vertex Pharmaceuticals in the Healthcare sector, alongside Biogen (BIIB), Gilead Sciences (GILD) and Incyte (INCY).
If you are researching Vertex Pharmaceuticals, also look at Biogen (BIIB), Gilead Sciences (GILD) and Incyte (INCY). You can compare all of them side by side or browse the full Healthcare sector on Sterling.
Q3 2016-Q2 2026
Q3 2016-Q2 2026